Business context and reporting period
Entity mismatch: Although the request identifies Tango Therapeutics, Inc., this filing is BCTG Acquisition Corp.’s 2020 Form 10-K. It is a blank-check company seeking a business combination, with an intended focus on biotechnology in North America and Europe. The filing is not Tango Therapeutics’ annual report.
The fiscal year ended December 31, 2020; the financial results cover May 21, 2020 (inception) through year-end, not Q4 alone. BCTG had not selected a target or signed a definitive acquisition agreement by the reporting date.
Financial metrics
| Metric | Reported amount or status |
|---|---|
| Operating revenue | None; the company had not begun operations beyond formation, its IPO, and target search. |
| Net loss | $123,046 for the inception-to-year-end period. |
| Income and expenses | $65,246 interest income; $108,865 general and administrative expense, $40,000 related-party administrative expense, $32,563 franchise tax expense, and $6,864 income tax expense. |
| Cash flow | $327,423 used in operating activities; $166.75 million used in investing activities to fund the trust; $168.39 million provided by financing activities. Year-end cash was $1.314 million. |
| Liquidity and assets | Working capital was approximately $1.4 million. Trust investments were $166.815 million; total assets were $168.313 million. |
| Debt and liabilities | No working-capital loans were outstanding. Total liabilities were $5.951 million, including $5.836 million of deferred underwriting commissions payable only if a business combination closes. |
| Equity and redemptions | $157.362 million was classified as temporary equity for 15,736,221 shares subject to possible redemption. Permanent stockholders’ equity was $5.000 million. |
| Margins | Not meaningful: BCTG had no operating revenue. |
Changes versus the prior comparable period
No prior-year comparable results are presented because BCTG was incorporated in May 2020. It completed its IPO on September 8, 2020, raising $166.75 million gross, and a concurrent $5.335 million sponsor private placement. Approximately $166.8 million was placed in the trust account.
Outlook, risks and unusual items
- Management said available working capital and borrowing capacity should cover needs through the earlier of a business combination or one year from the filing. The company had 24 months from the IPO closing—through September 8, 2022—to complete a transaction, absent an approved extension.
- If no transaction is completed within that period, BCTG must wind up and redeem public shares, subject to creditor claims and applicable law. Trust distributions could be reduced by claims; insider indemnification may not be collectible.
- The sponsor committed to purchase at least 2.5 million shares for $25 million in a private placement around the transaction closing. New issuance and transaction financing could dilute public investors.
- Management said the COVID-19 pandemic’s specific impact was not readily determinable; the financial statements include no related adjustments.
- Management identified potential conflicts from officers’ and directors’ other biotechnology and investment affiliations. Related-party arrangements include $10,000 monthly office and administrative support fees paid to a sponsor affiliate.
- Disclosure controls were assessed as effective. The filing contains no management assessment or auditor attestation on internal control over financial reporting, citing the new-public-company transition and applicable reporting exemptions.
- The audited financial statements received an unqualified opinion. No material litigation was reported.
Key facts for investors to verify
- Confirm the intended issuer: this filing is for BCTG Acquisition Corp., not Tango Therapeutics, Inc.
- Verify the trust balance, redemption terms, business-combination deadline, and any subsequent transaction or deadline extension.
- Review the sponsor’s $25 million share-purchase commitment, deferred underwriting fee, and potential dilution from additional financing.
- Assess the risks that creditor claims or uncollectible insider indemnification could reduce trust proceeds available to public shareholders.
- Check subsequent filings for changes in liquidity, target-search status, related-party arrangements, or the reported COVID-19 uncertainty.